Invesaro

Stocks Health care AVNS

NYSE · Health care

Avanos Medical, Inc. (AVNS)

Avanos Medical, Inc. brought in $715.9M of revenue over the twelve months to March 31, 2026, up 3.9% from a year earlier. It posted a net loss of $74.4M. Operating cash flow minus capital spending left $43.1M of free cash flow in fiscal 2025. At March 31, 2026 it held $65.6M in cash against $87.3M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on May 5, 2026.

Watch AVNS in 60 seconds
Revenue (last 12 months)
$715.9M
+3.9% year on year
Net margin
-10.4%

What Avanos Medical, Inc. does

Avanos Medical, Inc. is registered with the SEC under industry code SIC 3842 (Orthopedic, Prosthetic & Surgical Appliances & Supplies). Its shares trade on NYSE under the ticker AVNS.

Revenue and profit by year

Revenue
FY18: $652.3M $652.3M FY18FY19: $697.6M $697.6M FY19FY20: $714.8M $714.8M FY20FY21: $587M $587M FY21FY22: $684.1M $684.1M FY22FY23: $673.3M $673.3M FY23FY24: $687.8M $687.8M FY24FY25: $701.2M $701.2M FY25
Net income
FY18: $57.5M $57.5M FY18FY19: -$45.9M -$45.9M FY19FY20: -$29M -$29M FY20FY21: $6.3M $6.3M FY21FY22: $50.5M $50.5M FY22FY23: -$61.8M -$61.8M FY23FY24: -$392.1M -$392.1M FY24FY25: -$72.9M -$72.9M FY25

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal yearRevenueOperating incomeNet incomeDiluted EPSFree cash flow
2025$701.2M-$61.6M-$72.9M-$1.57$43.1M
2024$687.8M-$396.2M-$392.1M-$8.53$82.9M
2023$673.3M$4.2M-$61.8M-$1.32$14.6M
2022$684.1M$35.5M$50.5M$1.07$71.6M
2021$587M-$39M$6.3M$0.13$66.3M
2020$714.8M-$48.5M-$29M-$0.61-$22.7M

Full financial statements: income, balance sheet and cash flow

Where AVNS ranks in Health care

Revenue$701.2M
#175 of 646 in Health care · Top 27%
Revenue growth+1.9%
#348 of 474 in Health care · Bottom 27%
Net margin-10.4%
#258 of 485 in Health care · Bottom 47%
Free cash flow margin6.1%
#150 of 440 in Health care · Top 34%

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Health care

Latest SEC filings

What Avanos Medical, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

  1. August 6, 2026
  2. July 31, 2026
  3. July 31, 2026
  4. July 30, 2026
  5. July 27, 2026
  6. July 22, 2026
  7. July 15, 2026
  8. July 15, 2026
  9. July 2, 2026
  10. July 2, 2026

Recent insider filings (Forms 3, 4 and 144): 10, the latest on July 28, 2026. Insider transactions on SEC

What is AVNS worth? A DCF from its reported cash flow

Insider trades

What the people running Avanos Medical, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider bought or sold shares on the open market in the last 90 days. The 15 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.

Bought (open market)
$0
last 90 days
Sold
$0
last 90 days
DateInsiderWhatSharesPriceValueFiling
July 27, 2026 Blackford GaryDirector Other changeindirect 40,000 $25.00 $1M Form 4
July 27, 2026 Blackford GaryDirector Other change 79,590 $25.00 $2M Form 4
July 27, 2026 Egbuonu-Davis LisaDirector Other change 13,811 $25.00 $345.3K Form 4
July 27, 2026 Franchini Indrani LallDirector Other change 4,817 $25.00 $120.4K Form 4
July 27, 2026 Oleary Patrick JDirector Other change 54,640 $25.00 $1.4M Form 4
July 27, 2026 Shimer Julie AnnDirector Other change 50,090 $25.00 $1.3M Form 4
July 27, 2026 Pacitti DavidChief Executive Officer Other change 322,194 $25.00 $8.1M Form 4
July 27, 2026 Pacitti DavidChief Executive Officer Received as pay 444,730 - - Form 4
July 27, 2026 Pacitti DavidChief Executive Officer Other change 444,730 $25.00 $11.1M Form 4
July 27, 2026 Galovan Scott MichaelSVP, Chief Financial Officer Other change 135,596 $25.00 $3.4M Form 4
July 27, 2026 Galovan Scott MichaelSVP, Chief Financial Officer Received as pay 96,121 - - Form 4
July 27, 2026 Galovan Scott MichaelSVP, Chief Financial Officer Other change 96,121 $25.00 $2.4M Form 4
July 27, 2026 Delgado SigfridoSVP, Operations Other change 55,741 $25.00 $1.4M Form 4
July 27, 2026 Delgado SigfridoSVP, Operations Received as pay 54,886 - - Form 4
July 27, 2026 Delgado SigfridoSVP, Operations Other change 54,886 $25.00 $1.4M Form 4

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns AVNS

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

HolderOf classSharesFiled
Vanguard Capital Management13G, passive 5% 2,344,195 July 31, 2026

Latest filings below 5%: Armistice Capital, LLC 4.3% (May 15, 2026); T. Rowe Price Investment Management, Inc. 3.7% (May 7, 2026); The Vanguard Group 0% (March 26, 2026); RGM Capital, LLC 0% (February 13, 2026).

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

We have not read this company's Form 4 filings yet.

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about AVNS

What does Avanos Medical, Inc. do?

Avanos Medical, Inc. is registered with the SEC under industry code SIC 3842 (Orthopedic, Prosthetic & Surgical Appliances & Supplies). Its shares trade on NYSE under the ticker AVNS.

Is Avanos Medical, Inc. profitable?

No. Over the twelve months to March 31, 2026 it reported a net loss of $74.4M on revenue of $715.9M.

How much revenue does Avanos Medical, Inc. make?

Over the twelve months to March 31, 2026 Avanos Medical, Inc. reported revenue of $715.9M. That is 3.9% more than a year earlier.

When did Avanos Medical, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on May 5, 2026. It covers the period to March 31, 2026. Its newest filing of any kind is the deregistration from August 6, 2026.

Similar companies

Compare AVNS with

Compare AVNS with any company

Follow AVNS

Get an email when Avanos Medical, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow AVNS: get an email when it files

Where the numbers come from

Financial figures are the values Avanos Medical, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.